Clinical Trial

Imaging of Solid Tumors Using DLL3 SPECT

Withdrawn Early Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Sponsor funding
Summary
This is a single arm, pilot trial that evaluates the ability of a novel imaging agent (111In-ABD147) to detect metastatic cancer in participants with solid tumors. 111In-ABD147 is a high affinity Delta-like ligand 3 (DLL3) antigen binding domain fused to an engineered humanized Fc to create an antibody (VHH-Fc) that is bio-conjugated with a DOTA linker-chelator to a 111In radiometal. DLL3 is expressed on a variety of tumors, particularly those with neuroendocrine features.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-28; most recent amendment 2026-04-23.
Status change: Not Yet Recruiting → Withdrawn 2026-04-23
Trial Details
NCT Number NCT07052760
Lead Sponsor Thomas Hope
Collaborators: Abdera Therapeutics Inc.
Conditions Solid Tumor Cancer, Castration Resistant Prostate Cancer, Castration Resistant Prostate Cancer (CRPC), Neuroendocrine (NE) Tumors
Start Date 2026-04-30
Primary Completion 2028-05-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-29